Close this search box.

EMA’s CHMP recommends new indications for Dupixent, Skyrizi


May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy

By Gunjan Ohri, Data Content Analyst 

June 1, 2024 1:03 AM UTC

EMA’s CHMP recommended approval of seven new medicines and label expansions for six, including new indications for Dupixent and Skyrizi. 

In May’s review meeting, the committee issued a positive opinion on approval of Dupixent dupilumab from Sanofi (Euronext:SAN; NASDAQ:SNY) as an add-on therapy for chronic obstructive pulmonary disease, a large indication that would help scale Dupixent’s sales, a priority of Sanofi CEO Paul Hudson.